Full Text View
Tabular View
No Study Results Posted
Related Studies
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
This study has been completed.
Study NCT00788892   Information provided by Celator Pharmaceuticals

First Received on November 10, 2008.   Last Updated on May 16, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Myeloid Leukemia
Additional conditions recognized in this trial
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
CPX-351
Cytarabine + Daunorubicin - 7 and 3
Additional drug interventions recognized in this trial
Cytarabine
Daunorubicin
More general drug interventions related to this trial
Anti-Infective Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Celator Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services